Chemotherapy-induced hyperpigmentation

Chemotherapy-induced hyperpigmentation is a condition characterized by the darkening of the skin and/or nails that occurs as a side effect of certain chemotherapy drugs. This condition is a form of hyperpigmentation, which refers to the darkening of an area of skin or nails caused by increased melanin. Chemotherapy-induced hyperpigmentation can affect patients undergoing treatment for cancer, and its appearance can vary widely among individuals, depending on a variety of factors including the type of chemotherapy drug, the dosage, and the patient's skin type.

Causes

Chemotherapy-induced hyperpigmentation is primarily caused by the direct effects of chemotherapy drugs on melanocytes, the cells in the skin responsible for producing melanin. Some chemotherapy drugs can stimulate melanocytes to produce more melanin than normal, leading to hyperpigmentation. The exact mechanism by which these drugs affect melanocytes is not fully understood, but it is believed to involve the drug's interaction with the melanin synthesis pathways.

Common Drugs Associated with Hyperpigmentation

Several chemotherapy drugs have been associated with hyperpigmentation, including but not limited to:

• Cyclophosphamide
• Doxorubicin
• Busulfan
• Thiotepa
• 5-Fluorouracil

Symptoms

Symptoms of chemotherapy-induced hyperpigmentation include but are not limited to:

• Darkening of the skin in certain areas or throughout the body
• Dark streaks on the nails or darkening of the nail beds
• Darkening of the mucous membranes, such as the inside of the mouth

Diagnosis

Diagnosis of chemotherapy-induced hyperpigmentation is primarily clinical, based on the patient's history of chemotherapy and the appearance of the skin changes. Dermatologists may also perform a skin biopsy to rule out other causes of hyperpigmentation.

Treatment

Treatment for chemotherapy-induced hyperpigmentation focuses on managing the symptoms, as the condition often resolves on its own after the completion of chemotherapy. Options may include:

• Topical treatments to lighten the skin, such as hydroquinone
• Sun protection to prevent further darkening of the affected areas
• In some cases, laser therapy or chemical peels may be considered to reduce hyperpigmentation

Prevention

Preventive measures are limited but may include the use of sun protection to minimize sun exposure, which can exacerbate hyperpigmentation. Patients undergoing chemotherapy are advised to discuss potential side effects, including skin changes, with their healthcare provider.

Conclusion

Chemotherapy-induced hyperpigmentation is a side effect of certain chemotherapy drugs that results in the darkening of the skin and nails. While it can be concerning for patients, it is usually temporary and resolves after the completion of chemotherapy. Management focuses on symptom relief and prevention of further darkening.

‎